Abstract
In this study, we describe the activity of CT1746, an orally-active synthetic MMP inhibitor that has a greater specificity for gelatinase A, gelatinase B and stromelysin than for interstitial collagenase and matrilysin, in a nude mouse model that better mimics the clinical development of human colon cancer. The model is constructed by surgical orthotopic implantation (SOI) of histologically-intact tissue of the metastatic human colon tumor cell line Co-3. Animals were gavaged with CT1746 twice a day at 100 mg/kg for 5 days after the SOI of Co-3 for 43 days. In this model CT1746 significantly prolonged the median survival time of the tumor-bearing animals from 51 to 78 days. Significant efficacy of CT1746 was observed on primary tumor growth (32% reduction in mean tumor area at day 36), total spread and metastasis (6/20 treated animals had no detectable spread and metastasis at autopsy compared to 100% incidence of secondaries in control groups). Efficacy of CT1746 could also be seen on reducing tumor spread and metastasis to individual organ sites such as the abdominal wall, cecum and lymph nodes compared to vehicle and untreated controls. We conclude that chronic administration of a peptidomimetic MMP inhibitor via the oral route is feasible and results in inhibition of solid tumor growth, spread and metastasis with increase in survival in this model of human cancer, thus converting aggressive cancer to a more controlled indolent disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Liotta LA, Steeg PS and Stetler-Stevenson W, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327–36.
Ray JM and Stetler-Stevenson WG, 1995, Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J, 14, 908–17.
Frisch SM, Reich R, Collier IE, Genrich LT, Martin G and Goldberg GI, 1990, Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. Oncogene, 5, 75–83.
Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B-16 F10 melanoma cells. Cancer Res, 48, 5539–45.
DeClerk YA, Perez N, Shimada H, et al. 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701–8.
Anderson IA, Shipp MA, Docherty AJP and Teicher BA, 1996, Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewig lung carcinoma. Cancer Res, 56, 715–8.
Wang X, Fu X, Brown PD, Crimmin MJ and Hoffman RM, 1994, Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res, 54, 4726–28.
Goldmann E, 1907, The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet, 2, 1236–40.
Galardy RE, Grobelny D, Foellmer HG and Fernandez LA, 1994, Inhibition of angiogenesis by the matrix metalloproteinase inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentonyl)]-L-tryptophan methylamide. Cancer Res, 54, 4715–18.
Taraboletti G, Garofalo A, Bellotti D, et al. 1995, Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst, 87, 293–8.
Braverman AS, 1993, Chemotherapeutic failure: resistance or insensitivity. Ann Int Med, 118, 630–2.
Hoffman RM, 1992, Patient-like models of human cancer in mice. Curr Perspec Molec Cell Oncol, 1(B), 311–29.
Hoffman RM, 1994, Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem, 56, 1–3.
Fu X, Guadagni F and Hoffman RM, 1992, A metastatic nude-mice model of human pancreatic cancer constructed orthotopically from histologically-intact patient specimens. Proc Natl Acad Sci, USA, 89, 5645–9.
Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M and Hoffman RM, 1993, Orthotopic transplantation of histologically-intact clinical specimens of stomach cancer to nude mice: correlation of metastasis sites in mouse and human. Int J Cancer, 53, 608–12.
Chander SK, Antoniw P, Beeley NRA, et al. 1995, An in vivomodel for screening peptidomimetic inhibitors of gelatinase A. J Pharm Sci, 84, 404–9.
Kubota T, Shimosato Y and Nagai K, 1978, Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice. Gann, 68, 299–309.
Murphy G, Willenbrock F, Ward RV, et al. 1992, The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J, 283, 637–41.
Henderson B, Docherty AJP and Beeley NRA, 1990, Design of inhibitors of cartilage destruction. Drugs Future, 15, 496–508.
Beeley NRA, Ansell PRJ and Docherty AJP, 1994, Inhibitors of matrix metalloproteinase (MMPs). Curr Opinion Ther Patents, 4, 7–16.
Beckett RP, Davidson AH, Drummond AH, Huxley P and Whittaker M, 1996, Recent advances in matrix metalloproteinase inhibitor research. DDT, 1, 16–26.
Nagase H, Okada Y, Suzuki K, Enghild JJ and Salvesen G, 1991, Substrate specificities and activation mechanisms of the precursors of matrix metalloproteinases. Biochem Soc trans, 19, 715–18.
Crabbe T, O'Connell JP, Smith BJ and Docherty AJP, 1994, Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry, 33, 14419–25.
Tsuruo T, Yamori T, Naganuma K, Tsukagoshi S, and Sakurai Y, 1983, Characterisation of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Res, 43, 5437–42.
Richman PI and Bodmer WF, 1988, Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions. J Pathol, 156, 197–211.
Wortis HH, 1971, Immunological responses of "nude" mice. Clin Exp Immunol, 8, 305–17.
Huning T and Bevan MJ, 1980, Specificity of cytotoxic T cells from athymic mice. J Exp Med, 152, 688–702.
Minato N, Reid L, Neighbour A, Bloom BR and Holland J, 1980, Interferon, NK cells and persistent virus infection. Ann NY Acad Sci, 350, 42–52.
Sharp AK and Colston MJ, 1984, The regulation of macrophage activity in congenitally athymic mice. Eur J Immunol, 14, 102–5.
Benomar A, Gerlier D and Doré JF, 1986, Interaction with host macrophages and ability of human melanoma cell lines to grow in nude mice. Int J Cancer, 38, 419.
Herberman RB, Nunn ME, Holden HT, Staal S and Djeu JY, 1977, Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic large T cells. Int J Cancer, 19, 555.
Porter JR, Beeley NRA., Boyce BA, et al. 1994, Potent and selective inhibitors of gelatinase A I. Hydroxamic acid derivatives. Bioorg Med Chem Lett, 4, 2741–6.
Kleinwert HD, Baker WR and Stein HH, 1993, Orallyactive peptide-like molecules: a case history. Biopharmacology, 6, 36–41.
Goetzl EJ, Banda MJ and Leppert D, 1996, Matrix metalloproteinases in immunity. J Immunol, 156, 1–4.
Mahadevan V, Hart IR and Lewis GP, 1989, Factors influencing blood supply in wound granuloma quantified by a new in vivotechnique. Cancer Res, 49, 415–19.
Schipper H, Goh CR and Wang TL, 1995, Shifting the cancer paradigm: must we kill to cure? J Clin Oncol, 13, 801–7.
Furr BJ and Jordan VC, 1984, The pharmacology and clinical uses of tamoxifen. Pharmacol Ther, 25, 127–205.
Warrell RP, Frankel SR, Miller WH, et al. 1991, Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Engl J Med, 324, 1385–93.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
An, Z., Wang, X., Willmott, N. et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15, 184–195 (1997). https://doi.org/10.1023/A:1018461112732
Issue Date:
DOI: https://doi.org/10.1023/A:1018461112732